Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bayer’s Japan Open Innovation Center Now Up and Running
September 22, 2014
- Sadao Furuichi to Double as Heads of Kracie Pharma, Kracie Pharmaceutical
September 22, 2014
- Huya Bioscience International Opens Tokyo Office
September 19, 2014
- MTPC Generic Arm Seeks to Quickly Broaden Product Lineup, New Alliance a Possibility: Pres.
September 18, 2014
- Takeda to Reshuffle Global Structure in April
September 18, 2014
- Toray Partners with German Firm on Sales of Hemoperfusion Device in Europe
September 18, 2014
- Allergan, Shionogi Tie Up for Sales of Eyelash Hypotrichosis Agent
September 18, 2014
- Bayer Paid 10.1 Billion Yen to Healthcare Professionals in 2013
September 18, 2014
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
- Eli Lilly, AstraZeneca to Codevelop BACE Inhibitor for AD Treatment
September 18, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
- Novartis Files Jakavi for Polycythemia Vera in Japan
September 17, 2014
- Nippon Shinyaku to Gear Up R&D, Commercialization of Nucleic Acid Products
September 17, 2014
- Takeda Picks Teva’s Gerard Greco as Global Quality Officer
September 17, 2014
- Sanofi Taps Call Center to Prevent Patient Dropouts from Insulin Therapy
September 16, 2014
- Pharmacy Chains Hurrying to Reach Price Settlements with Wholesalers ahead of Sept.-End Deadline
September 16, 2014
- Novartis Pharma Paid 22.9 Billion Yen to Healthcare Professionals in 2013
September 16, 2014
- AstraZeneca’s 2013 Payments to Healthcare Professionals Reach 7.5 Billion Yen
September 16, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…